Green Cross specializes in the development of essential but difficult-to-make drugs
Prior to 1990, the average lifespan for a person with hemophilia in S.Korea was only 18 years, compared to 60 years for a person with hemophilia in Germany. Taking upon itself the mission to extend both quality of life and life expectancy for Koreans suffering from this disorder, Green Cross found success in Facnyne (plasma-derived factor IX) and Green VIII (plasma-derived factor VIII). It went on to develop Green Gene, a recombinant protein, and then Green Gene-F, which was made safer by removing albumin. Thanks to these innovative endeavors, the average lifespan of patients with hemophilia has increased to 74 years today. Refusing to rest on its laurels, Green Cross continues to develop long-acting and new-antibody cures for hemophilia.
Green Cross, a world-renowned expert on plasma-derived products, continues to enhance its already government-approved products by improving quality and diversifying available doses and types. The company is rapidly expanding abroad, starting with the launch of its immunoglobulin (IVIG-SN)in the U.S. market.
After the dawn of the new millennium, Green Cross began to expand its exclusive vaccine manufacturing facilities and accelerate its related R&D. The company played a major role in protecting the nation against the H1N1 flu virus, a pandemic that swept across the world in 2009, through development and release of its GC Flu (a seasonal trivalent flu vaccine, government-approved in 2009) and Green Flu-S (2009), as well as Green Flu-S Plus (2010), which contained immunity enhancers. Green Cross’ research success garnered recognition for the company as an exemplary model at the World Health Organization (WHO) meetings. Accordingly, our flu vaccines became the first in Asia and the fourth in the world to win WHO prequalification, a necessary step to participate in international bidding. In 2015, GC Flu became the first in Korea and the second in the world to win prequalification for a quadrivalent flu vaccine (GC Flu Quadrivalent), raising expectations for an expanding presence on the global market.
In 2016, Green Cross also became the first Korean developer and manufacturer of a Td vaccine, protecting the population against diphtheria and tetanus. The company intends to research and develop a new vaccine (Tdap or DTaP) to immunize against tetanus, diphtheria, and pertussis together.
Green Cross has access to a variety of vaccine pipelines, and continues to further develop its already government-approved vaccines to meet global standards.
Vaccines form another key interest area for Green Cross . Green Cross became the third company in the world to develop its own formula for preventing hepatitis-B, named Hepavax-B(government-approved in 1983). The company went on to become the first in the world to develop a vaccine against hemorrhagic fever with renal syndrome, named Hantavax (government-approved in 1990), and the second in the world to develop a varicella zoster vaccine, named Suduvax (government-approved in 1993). These achievements served to strengthen its reputation as a pioneer in vaccines.
With its expertise in plasma-derived products, vaccines, and recombinant protein treatments,
the company will maximize the value of its existing products, harness its disease-fighting R&D
pipelines, and continue to use strategic R&D innovation to develop new drugs.